(2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine
C22H34N4O — CID 162723889
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine
(2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine (PubChem CID 162723889) has the molecular formula C22H34N4O and a molecular weight of 370.54 g/mol. Its IUPAC name is (2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine.
Molecular Properties
| Compound Name | (2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine |
|---|---|
| PubChem CID | 162723889 |
| Molecular Formula | C22H34N4O |
| Molecular Weight | 370.54 g/mol |
| Exact Mass | 370.27 |
| IUPAC Name | (2R,5S)-2-[2-(4-tert-butylcyclohexyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methylmorpholine |
| SMILES | Cc1cc([C@H]2CN[C@@H](C)CO2)n2nc(C3CCC(C(C)(C)C)CC3)cc2n1 |
| InChI | InChI=1S/C22H34N4O/c1-14-10-19(20-12-23-15(2)13-27-20)26-21(24-14)11-18(25-26)16-6-8-17(9-7-16)22(3,4)5/h10-11,15-17,20,23H,6-9,12-13H2,1-5H3/t15-,16?,17?,20+/m0/s1 |
| InChIKey | IOEPEUSICCCRSV-MVBPIPQGSA-N |
| XLogP | 4.41 |
| TPSA | 51.45 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 370.54 |
| LogP ≤ 5 | 4.41 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162723889 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.